Clinical Trial Update: Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a targeted magnetic resonance imaging contrast agent in patients with prostate cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Targeted MRI contrast agent

Snippet

Sponsor: Songqi Gao | Conditions: MRI Scan | Phase 1, Phase 2 | Status: RECRUITING